Search research articles
Contact Us
Filters
Showing results (91-100 of 127) with videos related to
Page
of 13
Sort By:
APL Bioengineering
|
May 10, 2019
Non-steric-zipper models for pathogenic α-synuclein conformers
Brock Schuman, Amy Won, Koroboshka Brand-Arzamendi, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
September 18, 2015
Reproducibility of a Parkinsonism-related metabolic brain network in non-human primates: A descriptive pilot study with FDG PET
Yilong Ma, Tom H Johnston, Shichun Peng, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
July 31, 2003
Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease
Juha-Matti Savola, Michael Hill, Mia Engstrom, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|
May 13, 2011
Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-time
Philippe Huot, Tom H Johnston, Katie D Lewis, et al.
Acta Neuropathologica Communications
|
February 2, 2017
AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease
Chi Wang Ip, Laura-Christin Klaus, Akua A Karikari, et al.
Neuropharmacology
|
January 23, 2014
UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset
Philippe Huot, Tom H Johnston, Katie D Lewis, et al.
Neuropharmacology
|
December 4, 2017
DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease
Tom H Johnston, Eboo Versi, Patrick A Howson, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|
August 25, 2006
Phenotype of striatofugal medium spiny neurons in parkinsonian and dyskinetic nonhuman primates: a call for a reappraisal of the functional organization of the basal ganglia
Agnes Nadjar, Jonathan M Brotchie, Celine Guigoni, et al.
Experimental Neurology
|
November 3, 2020
A novel dopamine D3R agonist SK609 with norepinephrine transporter inhibition promotes improvement in cognitive task performance in rodent and non-human primate models of Parkinson's disease
Jay S Schneider, Courtney A Marshall, Lauren Keibel, et al.
Journal of Neuroinflammation
|
December 31, 2022
Expansion of regulatory T cells by CD28 superagonistic antibodies attenuates neurodegeneration in A53T-α-synuclein Parkinson's disease mice
Mohammad Badr, Rhonda L McFleder, Jingjing Wu, et al.
Page
of 13
Search research articles
Search
Showing results (91-100 of 127) with videos related to
Sort By:
Page
of 13
APL Bioengineering
|
May 10, 2019
Non-steric-zipper models for pathogenic α-synuclein conformers
Brock Schuman, Amy Won, Koroboshka Brand-Arzamendi, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
September 18, 2015
Reproducibility of a Parkinsonism-related metabolic brain network in non-human primates: A descriptive pilot study with FDG PET
Yilong Ma, Tom H Johnston, Shichun Peng, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
July 31, 2003
Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease
Juha-Matti Savola, Michael Hill, Mia Engstrom, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|
May 13, 2011
Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-time
Philippe Huot, Tom H Johnston, Katie D Lewis, et al.
Acta Neuropathologica Communications
|
February 2, 2017
AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease
Chi Wang Ip, Laura-Christin Klaus, Akua A Karikari, et al.
Neuropharmacology
|
January 23, 2014
UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset
Philippe Huot, Tom H Johnston, Katie D Lewis, et al.
Neuropharmacology
|
December 4, 2017
DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease
Tom H Johnston, Eboo Versi, Patrick A Howson, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|
August 25, 2006
Phenotype of striatofugal medium spiny neurons in parkinsonian and dyskinetic nonhuman primates: a call for a reappraisal of the functional organization of the basal ganglia
Agnes Nadjar, Jonathan M Brotchie, Celine Guigoni, et al.
Experimental Neurology
|
November 3, 2020
A novel dopamine D3R agonist SK609 with norepinephrine transporter inhibition promotes improvement in cognitive task performance in rodent and non-human primate models of Parkinson's disease
Jay S Schneider, Courtney A Marshall, Lauren Keibel, et al.
Journal of Neuroinflammation
|
December 31, 2022
Expansion of regulatory T cells by CD28 superagonistic antibodies attenuates neurodegeneration in A53T-α-synuclein Parkinson's disease mice
Mohammad Badr, Rhonda L McFleder, Jingjing Wu, et al.
Page
of 13